IpilimumabN01 (Innovent Biologics)

伊匹木单抗N01(信达生物)

Report date: 2026/05/16 20:00:17

Base Information

Drug NameIpilimumabN01 (Innovent Biologics)
Drug Alias Name伊匹木单抗N01注射液 (信达生物)Ipilimumab biosimilar (Innovent Biologics)伊匹木单抗生物类似药 (信达生物)达伯欣IBI-310
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursMismatch Repair Deficient CancerMicrosatellite Instability +[16] 
Global Approved IndicationsColonic Neoplasms
Approved Indications in ChinaColonic Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2025/12/22
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovent Biologics IncShanghai Pulmonary HospitalInnovent Biologics (Hangzhou) Co., Ltd. +[6] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMismatch Repair Deficient CancerMicrosatellite Instability +[13] 
Inactive IndicationsColorectal NeoplasmsEsophageal NeoplasmsMelanoma

Other Information

ATC CodeL01XC11
Related LinksN/A